These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372 [TBL] [Abstract][Full Text] [Related]
6. [The comparison of biological characteristics between tumor-infiltrating lymphocytes and tumor-associated lymphocytes in ascites of epithelial ovarian carcinoma]. Kang S; Shen K; Lang J Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):607-10. PubMed ID: 10806687 [TBL] [Abstract][Full Text] [Related]
7. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3. Strauss G; Gückel B; Wallwiener D; Moldenhauer G Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216 [TBL] [Abstract][Full Text] [Related]
8. Induction of immunocellular resistance to IL-2-activated lymphocytes within ovarian carcinoma cells. Papadopoulos AJ; Han X; Matossian-Rogers A; Raju KS Gynecol Oncol; 1995 Jun; 57(3):388-94. PubMed ID: 7774843 [TBL] [Abstract][Full Text] [Related]
9. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077 [TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors. Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800 [TBL] [Abstract][Full Text] [Related]
12. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425 [TBL] [Abstract][Full Text] [Related]
13. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients. Schöndorf T; Engel H; Kurbacher CM; Brenne U; Kolhagen H; Göhring UJ; Scharl A; Mallmann P J Soc Gynecol Investig; 1998; 5(2):102-7. PubMed ID: 9509389 [TBL] [Abstract][Full Text] [Related]
14. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892 [TBL] [Abstract][Full Text] [Related]
15. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353 [TBL] [Abstract][Full Text] [Related]
16. [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells]. Yang WL; Cui H; Feng J; Chang XH; Fu TY; Ye X; Zhang H; Li XP; Wen HW; Feng LM; Tong CR Ai Zheng; 2004 Dec; 23(12):1639-45. PubMed ID: 15601552 [TBL] [Abstract][Full Text] [Related]
17. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494 [TBL] [Abstract][Full Text] [Related]
18. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes. Melioli G; Ferrari I; Casartelli G; Ragni N Gynecol Oncol; 1993 Mar; 48(3):301-7. PubMed ID: 8462898 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of bovine ocular squamous cell carcinoma: isolation, culture and characterization of lymphocytes present in the tumor. Rutten VP; De Jong WA; Klein WR; Den Otter W; Steerenberg PA; Ruitenberg EJ Anticancer Res; 1991; 11(3):1259-64. PubMed ID: 1888157 [TBL] [Abstract][Full Text] [Related]
20. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice. Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]